Last $36.85 USD
Change Today +0.25 / 0.68%
Volume 1.0M
SGEN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Clay B. Siegall Ph.D.

Co-Founder, Chairman, Chief Executive Officer and President, Seattle Genetics Inc.
AgeTotal Calculated CompensationThis person is connected to 43 board members in 4 different organizations across 4 different industries.

See Board Relationships
53$6,286,460
As of Fiscal Year 2013

Background*

Dr. Clay B. Siegall, Ph.D. co-founded Seattle Genetics Inc. in 1997 and has been its Chief Executive Officer since November 2002 and President since June 2000. Dr. Siegall has nearly 20 years of experience in cancer research and therapeutic drug development. Dr. Siegall served as Executive Vice President of Seattle Genetics Inc., from December 1997 to June 2000 and Chief Scientific Officer from December 1997 to November 2002. Dr. Siegall was with the Bristol-Myers Squibb ...

Read Full Background

Corporate Headquarters*

21823 30th Drive SE
Bothell, Washington 98021

United States

Phone: 425-527-4000
Fax: 425-527-4001

Board Members Memberships*

1997-Present
Co-Founder, Chairman, Chief Executive Officer and President
2005-Present
Director and Chairperson of Compensation Committee
2013-Present
Director
2014-Present
Independent Director and Member of Compensation Committee

Education*

PhD
George Washington University
BS
University of Maryland

Other Affiliations*

Annual Compensation*

Salary$722,917
Bonus$1,500
Total Annual Compensation$724,417

Stock Options*

Restricted Stock Awards$2,257,200
All Other Compensation$8,130
Exercised Options49,245
Exercised Options Value$1,475,110
Exercisable Options1,533,545
Exercisable Options Value$43,510,617
Unexercisable Options444,584
Unexercisable Options Value$6,387,198
Total Value of Options$51,372,924
Total Number of Options2,027,374

Total Compensation*

Total Annual Cash Compensation$1,384,547
Total Short Term Compensation$724,417
Other Long Term Compensation$2,265,330
Total Calculated Compensation$6,286,460
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $36.85 USD +0.25

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Ariad Pharmaceuticals Inc.
$749.8K
Simon E. Moroney Ph.D.Chairman of Management Board and Chief Executive Officer
Morphosys AG
€772.6K
Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Executive Officer and President
Genmab A/S
kr10.7M
Aijaz Tobaccowalla Managing Director, Additional Director, Member of Board Administrative Committee and Member of Nomination & Remuneration Committee
Pfizer Limited
30.3M
Michael L. Babich Chief Executive Officer, President and Director
INSYS Therapeutics, Inc.
$1.0M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.